Oral Loading of Phenobarbital to Achieve Therapeutic Effects in Pediatric Patients with Acute Repetitive Seizures

Jemima Grace D. Fronda, MD, Mel Michel G. Villaluz, MD, Cristina M. Cruz-Urbi, MD
Section of Child Neurology, Child Neuroscience Division, Philippine Children’s Medical Center, Quezon City, Philippines

Purpose: Intravenous phenobarbital has not been available at our institution since 2019. This study aimed to determine the effectiveness of oral phenobarbital loading at a dose of 15 to 20 mg/kg to achieve therapeutic serum levels and clinical seizure control in pediatric patients with acute repetitive seizures.

Methods: This is a retrospective single-center review of the medical records of pediatric patients admitted for acute repetitive seizures (from January 2019 to June 2022) at the Philippine Children’s Medical Center who were given an oral phenobarbital loading dose of 15 to 20 mg/kg with serum level measurements taken within 48 hours after oral loading.

Results: Eleven patients were given a single oral phenobarbital loading dose of 15 to 20 mg/kg, while 14 were given two doses of 10 mg/kg 12 hours apart. All 25 patients achieved therapeutic serum levels within 48 hours post-loading. Higher serum levels were seen at 48 hours (median, 19.8 μg/mL at 24 hours vs. 24.4 μg/mL at 48 hours). This difference was statistically significant at 5% (P=0.023), and the majority achieved adequate seizure control without requiring additional anti-seizure medications (76%). Transient drowsiness was the most commonly documented adverse effect.

Conclusion: Oral loading of phenobarbital at a dose of 15 to 20 mg/kg given as a single dose or in two divided doses is an effective and safe alternative to achieve therapeutic serum levels and adequate clinical seizure control at 24 hours post-loading. This may be a promising and useful intervention at centers without available intravenous phenobarbital.

Keywords: Phenobarbital; Pediatrics, Administration, oral; Seizures; Developing countries

Introduction

One of the oldest antiseizure medications (ASMs), phenobarbital is a gamma-aminobutyric acid (GABA) inhibitor that decreases neuronal excitability by increasing the frequency of chloride channel openings. It has almost complete (95%) oral bioavailability, low total clearance, and a long half-life of 72 to 144 hours [1-3]. Pheno-
unavailable at our institution, while the oral form has remained accessible. Although the maximum probability of its efficacy is delayed by up to 12 hours when given via the oral route, a few studies have utilized oral phenobarbital loading. In the 1980s, children at high risk for seizure relapse were given an oral phenobarbital dose of 15 mg/kg followed by a second dose of 3 to 5 mg/kg 12 hours later. Monitoring serum phenobarbital levels showed that the effective therapeutic range (12.6 to 22.3 mg/L) was achieved as early as 1-hour post-loading, with no seizure recurrences observed [6,7]. Oral phenobarbital was also administered as an alternative regimen to pediatric patients with refractory status epilepticus in South Africa as a single dose of 20 mg/kg. Serum concentrations at different time points post-loading demonstrated therapeutic serum levels as early as 4 hours, making this method effective even in an acute setting [8]. Neonates who presented with seizures were also given oral phenobarbital as a single dose of 20 mg/kg with serial serum level measurements taken. Therapeutic levels were seen in as early as 0.5 hours, and at 12 hours post-loading, 80% of the neonates had adequate serum levels [9]. The common acute adverse effects of phenobarbital include sedation, respiratory distress, and liver injuries, but these previous studies demonstrated that children could tolerate enteral loading of phenobarbital to a maximum dose of 80 mg/kg with no evidence of hypotension, arrhythmia, respiratory depression, or deterioration in liver function [6-9].

In our setting, oral phenobarbital has been used as a second- or third-line long-acting ASM for seizure control in patients with repetitive seizures at a total dose of 15 to 20 mg/kg, given as a single dose or in staggered doses to be completed in 24 to 48 hours [10]. As of this writing, only a few studies are available for review, and no local data are available. This study thus aimed to determine whether oral phenobarbital can produce adequate serum therapeutic levels within 24 to 48 hours when given either as a single dose in a range of 15 to 20 mg/kg or in staggered doses of 10 mg/kg 12 hours apart. Specifically, this study also compared the different oral dosing regimens of phenobarbital in terms of the proportion of patients who achieved therapeutic serum levels, the rate of clinical seizure recurrence, and the acute adverse effects that were documented.

Materials and Methods

1. Patient selection
A retrospective review was conducted of the medical records of pediatric inpatients admitted from January 2019 to June 2022 for acute repetitive seizures at the Philippine Children’s Medical Center. Acute repetitive seizures previously known as cluster seizures are defined most commonly as seizures occurring more than three times in 24 hours with interictal period of 8 hours or less, or seizures occurring more than two times in 6 to less than 48 hours [11]. Patients aged 1 month to 18 years old were included if they were given either a single oral loading dose of 15 to 20 mg/kg/dose or two doses of 10 mg/kg 12 hours apart, with a serum level measurement taken within 24 to 48 hours from the initial loading dose. These patients may have had newly diagnosed epilepsy or were known epilepsy patients already on maintenance ASMs. Patients who were already maintained on phenobarbital were included if they had a history of missed doses for more than 24 hours or had laboratory-confirmed subtherapeutic levels. Patients who were given oral phenobarbital after another first-line ASM failed to control seizures were also included. Fig. 1 shows the distribution of the data samples collected.

Only convenience sampling was possible—The initial sample size computation was a minimum of 20 patients per arm satisfying the inclusion criteria, to determine, at 80% power, the effect of oral phenobarbital loading on serum phenobarbital levels, assuming that each subject had three measurements taken and intersubject variability was 50%. However, the number of samples obtained was not achieved from the total charts reviewed, and a total sample size of only 25 was obtained in this study. A total of 142 inpatient medical records with phenobarbital assays from the study period were reviewed. Of these, only 63 patients were given oral phenobarbital loading for acute repetitive seizures. Thirty-eight patients were excluded for various reasons (Fig. 1). The 25 patients who met the inclusion criteria were categorized into two groups: those who received a single dose and those with two doses. Seizure recurrences after oral loading and additional doses of phenobarbital or ASMs given to achieve clinical seizure control were also documented. If available from the records, information on liver function tests conducted within 24 to 48 hours after oral loading was also collected.

2. Statistical analysis
Summary statistics were reported as median (interquartile range [IQR]) for quantitative variables with skewed distribution and as percentage (count) for qualitative measures. The minimum and maximum values of continuous data were also reported. The Shapiro-Wilk test was used to determine whether continuous variables deviated from a Gaussian (normal) distribution. The chi-square test of independence was used to determine the significance of associations between two qualitative variables. The Mann Whitney U test was used to compare the serum phenobarbital levels between two groups. Statistical significance was based on a P ≤ 0.05. Stata version 15 (Stata Corp LLC, College Station, TX, USA) was used for data processing and analysis.
3. Ethics
Ethical approval was obtained from the Philippine Children’s Medical center Institutional Review Board (IR-EC #: PRCMC IR-EC 2021-041). This study adhered to the ethical consideration and principles set out in the Data Privacy Act of 2021 and the National Ethical Guidelines for Health and Health-Related research of 2017. Written informed consent from the patients was waived due to the retrospective nature of the study and patients’ information and results gathered were strictly kept confidential by removing any identifiers such as names, addresses, and contact numbers before further usage and analysis. The investigator, co-investigator, and supervising investigators have completed the Good Clinical Practice training on the responsible conduct of research with human subjects.

Results

1. Demographic and clinical data
Eleven patients (45.5% male) were given a single dose of oral phenobarbital loading, while 14 patients (50% male) were given two divided doses (Table 1). The median age was 2.9 years. Sixteen patients (64%) were diagnosed with epilepsy with structural etiologies. Focal motor seizures were seen in 23 patients (92%), and a co-existing illness during seizure occurrence was noted in 17 patients (68%), with pneumonia being the most common (10 patients, 40%). Five patients (20%) were already on phenobarbital maintenance, and three had missed doses for more than 24 hours for various reasons. Seven patients (28%) were maintained on a different ASM, with oral levetiracetam being the most common (in eight patients), followed by oral phenytoin. An intravenous benzodiazepine (diazepam/midazolam) was administered to 14 patients (56%) prior to oral phenobarbital loading. Intravenous levetiracetam was started in 10 patients (40%), followed by intravenous valproic acid in three patients (12%) without adequate seizure control before being given oral phenobarbital loading.

2. Determination of serum phenobarbital levels
Serum phenobarbital levels were determined once within 24 to 48 hours after oral loading (Fig. 2). The therapeutic range was defined as a serum level of 10 to 40 µg/mL—As indicated in our institution’s laboratory values. All 25 patients were able to achieve therapeutic serum levels within 48 hours post-loading. Twenty patients had an assay taken within 24 hours post-loading, with a median value of 19.8 µg/mL (IQR, 15.05 to 26.05), range from 13.5 to 79 Patients
79 Patients
no phenobarbital oral loading done

63 Patients
phenobarbital oral loading + acute repetitive seizures

38 Patients
excluded

2 Patients
status epilepticus

1 Patients
nonconvulsive status epilepticus

18 Patients
on phenobarbital maintenance with minimal serum therapeutic dose prior to oral loading

4 Patients
phenobarbital oral loading at 5 mg/kg/dose for 4 doses

25 Patients
fulfilled inclusion criteria

13 Patients
no phenobarbital assay done after post-loading

Fig. 1. Distribution of data samples included in the study. Within the study period, 142 patients had medical records documenting a phenobarbital assay. Only 63 patients had acute repetitive seizures and oral loading of phenobarbital. Thirty-eight patients did not meet the inclusion criteria and were excluded for the following reasons: 13 patients had no phenobarbital serum level measurements taken after the loading dose, 18 underwent oral loading but were already on phenobarbital maintenance with minimum therapeutic serum levels; four were given phenobarbital oral loading at 5 mg/kg/dose for 4 doses over 48 hours; two were given an oral phenobarbital loading dose to control clinical status epilepticus; and one had nonconvulsive status epilepticus.

https://doi.org/10.26815/acn.2022.00213
Table 1. Demographic and clinical profile of patients with oral loading of phenobarbital

| Characteristic                              | Oral loading of phenobarbital received |
|--------------------------------------------|---------------------------------------|
|                                            | 1 dose (15–20 mg/kg/dose) (n=11) | 2 doses (10 mg/kg/dose) (n=14) |
| Demographic                                |                                       |
| Sex                                        |                                       |
| Male                                       | 5 (45.5)                              | 7 (50.0)                                 |
| Female                                     | 6 (54.5)                              | 7 (50.0)                                 |
| Age in years                               |                                       |
| < 1                                        | 5 (45.5)                              | 4 (28.6)                                 |
| 1–5                                        | 2 (18.2)                              | 6 (42.9)                                 |
| 6–10                                       | 2 (18.2)                              | 3 (21.4)                                 |
| 11–18                                      | 2 (18.2)                              | 1 (7.1)                                  |
| Clinical profile                           |                                       |
| Seizure/epilepsy etiology                  |                                       |
| Structural                                 | 6 (54.5)                              | 10 (71.42)                               |
| Infectious/post-infectious                 | 1 (18.2)                              | 3 (14.3)                                 |
| Epilepsy syndrome                          | 1 (9.1)                               | 1 (7.1)                                  |
| Metabolic                                  | 2 (18.2)                              | -                                        |
| Unknown                                    | 1 (9.1)                               | -                                        |
| Characteristics of seizures                |                                       |
| Focal motor                                | 10 (90.9)                             | 13 (92.9)                                |
| Focal nonmotor                             | -                                     | 1 (7.1)                                  |
| Generalized, motor                         | 1 (9.1)                               | -                                        |
| Others (myoclonus, spasms)                | 1 (9.1)                               | 2 (14.2)                                 |
| Presence of comorbidities at time of admission/seizures |   |                                       |
| None                                       | 3 (27.3)                              | 5 (35.7)                                 |
| Cerebral palsy                             | 1 (9.1)                               | 2 (14.3)                                 |
| Pneumonia                                  | 3 (27.3)                              | 7 (50.0)                                 |
| Other infections (ventriculitis, URTI)     | 1 (36.4)                              | 5 (35.7)                                 |
| Missed doses of phenobarbital              | 1 (9.1)                               | 2 (14.3)                                 |
| Missed doses of other ASM                  | -                                     | 1 (7.1)                                  |
| Metabolic derangements                     | 1 (9.1)                               | -                                        |
| On phenobarbital maintenance medication   |                                       |
| Yes                                        | 3 (27.3)                              | 2 (14.3)                                 |
| No                                         | 8 (72.7)                              | 12 (85.7)                                |
| Other maintenance ASMs                    |                                       |
| Levetiracetam                              | 5 (45.5)                              | 3 (21.4)                                 |
| Valproic acid                              | -                                     | 1 (7.1)                                  |
| Phenytoin                                  | 3 (27.3)                              | 2 (14.3)                                 |
| Others                                     | 4 (36.4)                              | 1 (7.1)                                  |
| Other ASMs administered before phenobarbital |                       |                                       |
| None                                       | 1 (9.1)                               | 6 (42.9)                                 |
| Diazepam/midazolam                         | 7 (63.6)                              | 7 (50.0)                                 |
| Levetiracetam (intravenous)                | 5 (45.5)                              | 5 (35.7)                                 |
| Valproic acid (intravenous)                | 3 (27.3)                              | -                                        |
| Phenytoin (intravenous)                    | 2 (18.2)                              | -                                        |
| Oxcarbazepine (oral)                       | 1 (9.1)                               | -                                        |

Values are presented as number (%) among 25 patients given oral phenobarbital loading: 11 patients given a single dose of 15 to 20 mg/kg, and 14 patients given two doses of 10 mg/kg 12 hours apart.

URTI, upper respiratory tract infection; ASM, anti-seizure medication.

*aSome patients presented with multiple seizure types, comorbidities and maintenance medications.
Serum Pb levels ug/mL

Time Phenobarbital assay taken (hours)

20 mkdose as SD
20 mkdose in 2 divided dose

Fig. 2. Serum phenobarbital levels attained within 24 to 48 hours post-loading. The X-axis corresponds to the time in hours when the measurement was made, while the Y-axis corresponds to the serum levels of each patient. Patients who received a single dose of phenobarbital oral loading are shown in purple, while those who received two divided doses are colored green. The therapeutic range is marked by the orange area. Serum values ranged from 13.5 to 38.5 μg/mL at 24 hours and from 13.4 to 51 μg/mL at 48 hours.

Table 2. Comparison of median phenobarbital serum levels achieved at 24 and 24 hours after oral loading

| Time when phenobarbital assay taken | No. of patients | Median serum phenobarbital levels achieved per oral loading regimen (μg/mL) |
|------------------------------------|----------------|------------------------------------------------------------------------------|
|                                    | 24th-hour       |                                                                             |
|                                    | 20              | 25.98 (19.11–31.78)                                                         |
|                                    | 48th-hour       | 51                                                                          |
|                                    | 5               | 24.4 (17.45–37.15)                                                          |

Values are presented as median (interquartile range). The comparison of serum levels between the two oral loading regimens was significant at 5% (P=0.023).

38.5 μg/mL. These patients were 10 of 11 (90.9%) with single dose and 10 of 14 (71.4%) with two doses. There was a significant difference on the median serum levels between one dose group (25.98 mg/mL; IQR, 19.11 to 31.78) and two dose group (15.24 mg/mL; IQR, 13.96 to 27.37).

Five patients had an assay determined on the 48th hour post-loading with median serum phenobarbital levels of 27.4 μg/mL (IQR, 17.2 to 48.9), range from 13.4 to 51.0 μg/mL. Four of these received two doses (4 of 14, 28.6%) and one had a single dose (1 of 11, 9.1%). The median serum level in the four patients with two doses was 24.4 μg/mL (IQR, 17.45 to 37.15), range from 13.4 to 46.9 μg/mL.

The distribution of these patients and comparison between the two regimens did not show any statistical difference (P=0.245) in achieving therapeutic levels (Table 3). At 24 hours, higher median serum levels were found in patients given the single-dose regimen than in those given two doses (P=0.023) (Table 2).

The overall median serum phenobarbital level was 21.5 mg/mL (IQR, 15.14 to 27.37), range from 13.4 to 51.0 mg/mL. The median serum levels within 24 hours and 24 to 48 hours were 19.8 mg/mL (IQR, 15.02 to 26.45) and 27.4 mg/mL (IQR, 21.46 to 46.86). A comparison between these two groups showed marginal results (P=0.055), suggesting that the actual difference in serum levels could be either significant or not. This warrants further investigation through similar studies on a larger scale.

3. Seizure control and adverse effects

Clinical to seizure control between the two groups was not significantly different (P=0.548) (Table 4). Drowsiness was recorded in 18 patients (75%), without a significant difference between the two groups (P ≥ 0.067) (Table 5).
Table 3. Distribution and comparison of patients who achieved serum therapeutic levels after oral loading of phenobarbital

| Time when the phenobarbital assay was taken | Oral loading dose given | 1 dose (15–20 mg/kg/dose) (n = 11) | 2 doses (10 mg/kg/dose) (n = 14) |
|-------------------------------------------|------------------------|-----------------------------------|----------------------------------|
| 24 hours                                  | 20                     | 10 (90.9)                         | 10 (71.4)                        |
| 48 hours                                  | 5                      | 1 (9.1)                           | 4 (28.6)                         |

Values are presented as number (%) among 11 patients given a single dose of oral phenobarbital and 14 patients with two divided doses. The one-sided test of independence did not yield significant results (P=0.245).

Table 4. Comparison of seizure control in patients given an oral loading dose of phenobarbital

| Seizure recurrence | Oral loading dose given | 1 dose (15–20 mg/kg/dose) | 2 doses (10 mg/kg/dose) |
|--------------------|------------------------|---------------------------|------------------------|
| Patients without seizure recurrence | 19 | 8 (72.7) | 11 (78.6) |
| Patients with seizure recurrence | 6 | 3 (27.3) | 3 (21.4) |

Values are presented as number (%) among 11 patients given a single dose of oral phenobarbital and 14 patients with two divided doses. The one-sided test of independence did not yield significant results (P=0.548).

Table 5. Adverse effects noted after oral phenobarbital loading

| Adverse effects reported | Oral loading dose given | 1 dose (15–20 mg/kg/dose) | 2 doses (10 mg/kg/dose) |
|--------------------------|------------------------|---------------------------|------------------------|
| Drowsiness               | 18                     | 10 (90.9)                 | 8 (57.1)               |
| Decreased sensorium      | 4                      | 1 (9.1)                   | 3 (21.4)               |
| Elevated liver enzymes   | 3                      | 3 (27.3)                  | -                      |

Values are presented as number (%) among 11 patients given a single dose of oral phenobarbital and 14 patients with two divided doses. The one-sided test of independence did not yield significant results (P=0.067).

Discussion

Acute repetitive seizures are neurologic emergencies that may progress to status epilepticus if left untreated. Intravenous phenobarbital is a well-established second-line ASM used for acute repetitive seizures when the recommended benzodiazepines fail to control seizures [11-15]. In this retrospective review, children with acute repetitive seizures were given oral phenobarbital instead of the intravenous form due to the latter’s unavailability. As there are still no set recommendations for the actual doses and use of oral phenobarbital loading at our institution, this method was based on the available related literature and the attending neurologists’ experience.

Acceptable serum therapeutic levels may vary across laboratories, but are considered effective at 10 to 40 μg/mL [10]. After oral loading via a single dose or in two divided doses, the patients in this study were able to achieve therapeutic serum levels as early as 12 hours, with higher serum values at the 24-hour determination. Comparing these two dosing regimens demonstrated that higher serum levels were achieved at 24 hours with the single-dose regimen than with the two-dose regimen. In young children and infants, the bioavailability of phenobarbital is less than 50%, with systemic clearance of as long as 70 hours. A higher gastric pH in children also causes a decrease in the absorption rate [16,17]. These factors may contribute to the higher levels documented using the single dose regimen in the 24-hour test. At 48 hours, higher serum levels were seen, possibly due to the additional maintenance doses administered a few hours before the determination of serum concentration levels. These results show that an initial high oral loading dose is adequate to provide rapid plasma levels, which can be maintained with additional doses over the following days.

Phenobarbital is effective in focal seizures, the most common seizure type seen in this study [18]. Most patients who were given oral phenobarbital after intravenous benzodiazepine achieved clinical seizure control except for three patients. Two of these were cases of epilepsy syndromes (tuberous sclerosis complex and Lennox-Gastaut syndrome) with intractable seizures already maintained on other ASMs. Oral phenobarbital was administered orally for acute repetitive seizures, but initially had poor seizure control; thus, the maintenance doses were increased. Seizure reduction to 50% from baseline was noted 4 days post loading, and their serum levels at 48 hours showed slightly higher serum levels (46 and 51 μg/mL). The third patient was a previous case of status epilepticus who already had seizure control with three other ASMs with maxi-
oral doses before having repetitive seizures. He was given a single dose of 15 mg/kg oral phenobarbital, and repetitive seizures persisted over the next hour before clinical control was achieved. Phenobarbital oral loading was given to 13 patients after intravenous levetiracetam (40%), phenytoin (20%), or valproic acid (4%) was unable to achieve adequate seizure control despite maximum doses. After administration of oral phenobarbital, clinical seizure control was achieved in 10 patients (70%). Of the patients with persistent clinical seizures, one needed a subsequent increase in the maintenance dose; one was given another ASM (oxcarbazepine), and the other had no subsequent episode after the initial seizure recurrence, showing adequate seizure control after oral phenobarbital.

The acute adverse effects of phenobarbital include rashes, hypersensitivity reactions, somnolence, drowsiness, and acute liver dysfunction [10,18]. Drowsiness was the most commonly reported adverse effect in 18 patients and was noted to be transient, with recovery within 24 hours. Four patients (16%) had an associated decreased sensorium post-loading. Two of them had concomitant pneumonia requiring intubation. One was a case of aqueductal stenosis that eventually needed a ventriculoperitoneal shunt, and the other was a case of a posterior fossa mass that loped decreased sensorium after the second dose of oral loading was given. Improvement was noted after transiently withholding subsequent maintenance doses of phenobarbital for 24 hours before resumption. Most of the adverse effects documented in these patients depended on their comorbidities at the time of seizure occurrence. These findings are similar to those of previous studies of oral phenobarbital loading in children and neonates [8,9]. Liver function measures were only available in three patients. The two patients with elevated liver enzymes had a concomitant liver injury; one had jaundice on admission, while the other had a vitamin K deficiency. Similarly, phenobarbital in this setting did not directly cause acute liver injury after the oral loading doses were given. A comparison between the two dosing regimens in terms of these adverse effects also showed no significant difference between the two groups.

This study was limited due to its retrospective nature and small sample size. Because of the short interval for study inclusion and the non-routine phenobarbital serum monitoring, the study participants were limited. A review of patients’ medical records would also be unable to fully document all the adverse events that may occur in these patients. A prospective and broader-spectrum study is thus recommended.

This study showed that oral loading of phenobarbital at a dose of 15 to 20 mg/kg/day given as a single dose or in two divided doses is an effective and safe method for achieving serum therapeutic effects within 24 hours after oral loading. This serum level was maintained and increased with maintenance doses. Children were able to tolerate this method with minimal and transient adverse reactions. This practice may thus be a helpful alternative at centers without access to intravenous phenobarbital or other newer ASMs.

Conflicts of interest
No potential conflict of interest relevant to this article was reported.

ORCID
Jemima Grace D. Fronda, https://orcid.org/0000-0001-7577-0323

Author contribution
Conceptualization: JGDF, MMGV, and CMCU. Data curation: JGDF. Formal analysis: JGDF. Methodology: JGDF. Project administration: JGDF. Visualization: JGDF. Writing-original draft: JGDF. Writing-review & editing: JGDF, MMGV, and CMCU.

References
1. Bialer M. How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)? Epilepsia 2012;53 Suppl 8:3-11. Bialer M. How did phenobarbital’s chemical structure affect the development of subsequent antiepileptic drugs (AEDs)? Epilepsia 2012 53 Suppl 8:3-11.
2. Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia 2012;53 Suppl 8:40-6.
3. Tiamkao S, Suttapan K, Pranbul S, Tiamkao S, Savanyawisuth K; Integrated Epilepsy Research Group. Adjunctive enteral phenobarbital for adult status epilepticus: a brief report. Neuropsychiatr Dis Treat 2013;9:1829-34.
4. World Health Organization. Executive summary. In: Guidelines on neonatal seizures. Geneva: World Health Organization; 2011 [cited 2022 Aug 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK304095/.
5. Subcommitteee on Febrile Seizures; American Academy of Pediatrics. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics 2011;127:389-94.
6. Autret E, Billard C, Gold F, Laugier J, Breteau M. Use of phenobarbital by the oral route in the acute and maintenance treatment of convulsions in children. Arch Fr Pediatr 1983;40:579-83.
7. Alix D, Berthou F, Riche C, Castel Y. Plasma concentrations of
phenobarbital and dosage according to age. Dev Pharmacol Ther 1984;7 Suppl 1:164-70.
8. Wilmshurst JM, van der Walt JS, Ackermann S, Karlsson MO, Blockman M. Rescue therapy with high-dose oral phenobarbital loading for refractory status epilepticus. J Paediatr Child Health 2010;46:17-22.
9. Turhan AH, Atici A, Okuyaz C, Uysal S. Single enteral loading dose of phenobarbital for achieving its therapeutic serum levels in neonates. Croat Med J 2010;51:215-8.
10. Section of Pediatric Neurology, Department of Pediatrics, UP-Philippine General Hospital. Seizures in children: a guide to management. 2018. p. 106.
11. Almohaish S, Sandler M, Brophy GM. Time Is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines. J Clin Med 2021;10:1754.
12. Graham JK. A comparison of the absorption of phenobarbital given via the oral and the intramuscular route. Clin Exp Neurol 1978;15:154-8.
13. Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: where do we go from here? Bull World Health Organ 2001;79:344-51.
14. Cereghino JJ. Identification and treatment of acute repetitive seizures in children and adults. Curr Treat Options Neurol 2007;9:249-55.
15. Lee YJ, Yum MS, Kim EH, Ko TS. Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures. Korean J Pediatr 2016;59:35-9.
16. Shiraishi C, Matsuda H, Ogura T, Iwamoto T. Factors affecting serum phenobarbital concentration changes in pediatric patients receiving elixir and powder formulations. J Pharm Health Care Sci 2021;7:7.
17. Eadie MJ, Lander CM, Hooper WD, Tyrer JH. Factors influencing plasma phenobarbital levels in epileptic patients. Br J Clin Pharmacol 1977;4:541-7.
18. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63.